It should be noted that Gulati et al. performed the first-in-human trial of an anti-FAP CAR T cell therapy and demonstrated that a FAP CAR T cell therapy induced stable disease for 1 year in a patient with malignant pleural mesothelioma without any treatment-terminating toxicities51. This evidence concerns the gene FAP and malignant pleural mesothelioma.